MiR-222 promotes the progression of polycystic ovary syndrome by targeting p27 Kip1

Huang, Xiaolan; She, Liping; Luo, Xiangmin; Huang, Shu‐Zhen; Wu, Jinxiang

doi:10.1016/j.prp.2019.01.038

Cited by 16 publications

(12 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduction in miR-16 levels in PCOS could inhibit proliferation and promote apoptosis of ovarian granulosa cells (Fu et al, 2018). MiR-222 has been reported to promote proliferation and inhibit apoptosis of ovarian granulosa cells, thus promoting the progression of PCOS (Huang et al, 2019). MiR-3188 levels, with the ability to inhibit cell proliferation in non-small cell lung cancer (Wang et al, 2018) and head and neck cancer , were found to be increased in PCOS ovarian granulosa cells .…”

Section: Introductionmentioning

confidence: 97%

miR-3188 Regulates proliferation and apoptosis of granulosa cells by targeting KCNA5 in the polycystic ovary syndrome

et al. 2021

View full text Add to dashboard Cite

Abnormal proliferation of granulosa cells is implicated in ovarian dysfunction and dysregulated folliculogenesis in the polycystic ovary syndrome (PCOS). Aberrant microRNA (miRNA) expression might contribute to disordered folliculogenesis and granulosa cell proliferation in PCOS. This study aimed to investigate the roles of miR-3188 in ovarian dysfunction, as well as the mechanism involved in granulosa cell proliferation in PCOS. Firstly, peripheral blood samples were isolated from PCOS patients and healthy controls, and qRT-PCR analysis demonstrated a dramatic increase in miR-3188 in PCOS patients when compared to the healthy controls. Secondly, miR-3188 overexpression increased cell viability of the granulosa-like tumor cell line (KGN). However, cell viability of KGN was repressed by interference with miR-3188. MiR-3188 promoted cell cycle of KGN through increasing cyclinD1 and decreasing p21 levels. Moreover, cell apoptosis was suppressed by miR-3188 in KGN, indicated by enhanced Bcl-2, and reduced Bax and cleaved caspase-3 levels, whereas knockdown of miR-3188 resulted in opposite effects. Lastly, potassium voltage-gated channel subfamily A member 5 (KCNA5) was verified as a target of miR-3188. KCNA5 expression was decreased and displayed negative correlation with miR-3188 levels in PCOS patients. Overexpression of KCNA5 attenuated the promotive effects of miR-3188 on cell viability and cell cycle in KGN. In conclusion, miR-3188, a key miRNA enhanced in PCOS, promoted granulosa cell proliferation through down-regulation of KCNA5, providing a new therapeutic target for PCOS.

show abstract

Section: Introductionmentioning

confidence: 97%

miR-3188 Regulates proliferation and apoptosis of granulosa cells by targeting KCNA5 in the polycystic ovary syndrome

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The association between miR-222 and lipid metabolism is a known fact [ 25 ]. Moreover, miR-222 is implicated in PCOS [ 14 ]. This study investigated the correlation between miR-222-3p and glucose and lipid metabolism in PCOS patients.…”

Section: Discussionmentioning

confidence: 99%

“…miRNAs are implicated in PCOS pathogenesis [ 11 ] and are differentially expressed in PCOS patients and normal women, which is not unrelated to sex hormones and metabolism [ 12 , 13 ]. miR-222 is notably up-regulated in sera and tissues of PCOS patients [ 12 , 14 ], indicative of a close association with PCOS etiology. Increased miR-222-3p expression in sera of diabetic patients has a potential association with IR development [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Correlation study on serum miR-222-3p and glucose and lipid metabolism in patients with polycystic ovary syndrome

et al. 2022

View full text Add to dashboard Cite

Objective microRNAs (miRNAs) play pivotal roles in polycystic ovary syndrome (PCOS), an endocrine and metabolic disorder that commonly occurs in women of childbearing age. This paper aimed to measure miR-222-3p expression in sera of PCOS patients and to explore its clinical value on PCOS diagnosis and prediction of diabetic and cardiovascular complications. Methods Totally 111 PCOS patients and 94 healthy people were recruited and assigned to the overweight (ow) group and non-overweight (non-ow) group, followed by determination of serum miR-222-3p expression. The diagnostic efficiency of miR-222-3p on PCOS ow and non-ow patients was analyzed. Correlations between miR-222-3p and glycolipid metabolic indicators and diabetic and cardiovascular complications in PCOS were analyzed. The downstream target of miR-222-3p was predicted and their binding relationship was verified. The correlation between PGC-1α and miR-222-3p was analyzed. Results miR-222-3p was highly-expressed in PCOS patients (p < 0.001), in especially PCOS ow patients. The area under the curve (AUC) of miR-222-3p diagnosing PCOS non-ow patients was 0.9474 and cut-off value was 1.290 (89.06% sensitivity, 98.11% specificity), indicating that non-ow people with serum miR-222-3p > 1.290 could basically be diagnosed with PCOS. AUC of miR-222-3p diagnosing PCOS ow patients was 0.9647 and cut-off value was 2.425 (85.11% sensitivity, 100% specificity), suggesting that ow people with serum miR-222-3p > 2.425 could basically be diagnosed with PCOS. miR-222-3p was positively-correlated with fasting plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment–insulin resistance (HOMA-IR), and low-density lipoprotein cholesterol (LDL-C) and negatively-correlated with high-density lipoprotein cholesterol (HDL-C). miR-222-3p was independently-correlated with diabetic and cardiovascular complications in PCOS (p < 0.05). High expression of miR-222-3p predicted high risks of diabetic and cardiovascular complications in PCOS. miR-222-3p targeted PGC-1α and was negatively-correlated with PGC-1α (r = − 0.2851, p = 0.0224; r = − 0.3151, p = 0.0310). Conclusion High expression of miR-222-3p assisted PCOS diagnosis and predicted increased risks of diabetic and cardiovascular complications. miR-222-3p targeted PGC-1α and was negatively-correlated with PGC-1α.

show abstract

“…They also showed that miRNAs are involved in the homeostatic modification of steroid hormones, as well as target steroid receptors or steroid synthesis enzymes. miR-222, which was largely expressed in the follicular liquid and serum of PCOS patients (23), is an estrogen receptor regulator 1 (24). It was further reported that miR-320 targets the steroidogenic factor 1 (SF-1) gene although the expression of this miRNA was discrepant across different studies (17).…”

Section: Investigating the Mirnas Affecting Hormonalmentioning

confidence: 99%

Manifestly Altered MicroRNAs in Poly Cystic Ovary Syndrome

et al. 2020

View full text Add to dashboard Cite

MicroRNAs (miRNAs) constitute a large family of small non-coding RNAs which regulate gene expression at the surface following transcription. They are widely involved in many physiological and pathological processes including polycystic ovarian syndrome (PCOS). PCOS is an endocrine disorder in women. Currently, there is no comprehensive information about the role of miRNAs in PCOS. Thus, this paper has attempted to collate studies on miRNAs in order to determine important changes in their miRNA expression profile in the total blood, serum, plasma, follicular fluid, and granulosa cells in PCOS patients alongside the genes which are targeted for regulation by these miRNAs. This study presents a new approach for using miRNAs and their target genes for diagnosing and treating PCOS.

show abstract

MiR-222 promotes the progression of polycystic ovary syndrome by targeting p27 Kip1

Cited by 16 publications

References 24 publications

miR-3188 Regulates proliferation and apoptosis of granulosa cells by targeting KCNA5 in the polycystic ovary syndrome

miR-3188 Regulates proliferation and apoptosis of granulosa cells by targeting KCNA5 in the polycystic ovary syndrome

Correlation study on serum miR-222-3p and glucose and lipid metabolism in patients with polycystic ovary syndrome

Manifestly Altered MicroRNAs in Poly Cystic Ovary Syndrome

Contact Info

Product

Resources

About